ATB 200

Drug Profile

ATB 200

Alternative Names: AT GAA; AT-B200/AT2220; ATB 200+chaperone; ATB-200; ATB200/AT2221; rhGAA-Amicus Therapeutics

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amicus Therapeutics
  • Class Alpha-glucosidases; Enzymes
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glycogen storage disease type II

Most Recent Events

  • 07 Aug 2018 Amicus Therapeutics intends to complete a retrospective natural history study in approximately 100 ERT-treated Pompe patients in 2H 2018
  • 26 Jun 2018 Amicus Therapeutics announces intention to conduct meeting with the EMA for the potential regulatory pathway for conditional approval of ATB 200 for Glycogen storage disease type II (Pompe disease) in Europe in 2019
  • 26 Jun 2018 Amicus Therapeutics announces intention to conduct Type-C meeting with the US FDA for Glycogen storage disease type II (Pompe disease) in the third quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top